Navigation Links
Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
Date:5/22/2012

de proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, including statements relating to the timing of the commencement of Phase 1 clinical testing of UGP281 in humans, the risk of unwanted cardiovascular effects as compared to any other drug; whether the UGP281 preclinical results can be reproduced in humans, and if so, whether UGP281 could potentially offer a new treatment option; whether UGP281's selective receptor-binding will result in a cleaner and more attractive safety profile relative to any other drug; whether the Company can differentiate UPG281 from other potentially competitive, peptide-based drugs and drug candidates; whether the Company will be able to effectively develop UGP281 and position it in the marketplace; whether the Company will be able to successfully build a portfolio of proprietary partnerships based on its Peptelligence™ platform. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These known and unknown risk factors include, but are not limited to: the delay in obtaining or the failure to obtain regulatory approvals for our products and the products of our licensees that may generate royalty and milestone payments to us, our ability to achieve product sales and royalties, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies and our ability to enter into favorable new agreements with such companies, our ability to cut expenses and maintain effic
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
3. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
4. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
5. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
6. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
7. Soligenix Demonstrates Positive Proof of Concept with its Proprietary Vaccine Thermostabilization Technology
8. Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial
9. 10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
10. The New England Journal of Medicine Publishes Study Showing LigoCytes Norovirus Vaccine Demonstrates Protection Against Illness
11. Fujifilm Demonstrates the Latest Advancements of Synapse® PACS at RSNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... CHAPEL HILL, N.C. , May 1, 2015 /PRNewswire/ ... from payers for its high price but manufacturer Gilead ... programs, strategic worldwide pricing, and effective public relations campaigns. ... and promise of less severe side effects propelled the ... quarter of 2014, the therapy,s first quarter on the ...
(Date:5/1/2015)... N.J. , May 1, 2015 CANTEL MEDICAL ... A. Krakauer , Chief Executive Officer, will be presenting at ... the Encore at the Wynn in Las Vegas, ... May 14, 2015 at 10:00 AM PT/1:00 PM ET. In ... the day. An audio webcast will be ...
(Date:5/1/2015)... , May 01, 2015 Research and Markets ... the "US ACO IT Spending Outlook 2018" ... that number of lives covered by ACO would grow ... this report, the ACO IT spending has been studied ... on software and spending on services. Our research provides ...
Breaking Medicine Technology:New Study Examines Success Lessons of Sovaldi's and Harvoni's Blockbuster Launches 2United States ACO IT Spending Outlook 2014-2018 2
... 2011 The U.S. Food and Drug Administration today ... labels that include a new standardized format to improve ... differentiation. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... container labels for 16 solid oral drug products regulated ...
... Unity Management Group, Inc. (PINKSHEETS: UYMG) "UNITY" (or ... in Physician and Hospital Practice Management, Business Services, ... Calibration, Data Acquisition, and Equipment Distribution. ... (MCC) Metropolitan Computing Corporation has completed 5 major ...
Cached Medicine Technology:FDA Approves Redesigned Labels for Some Merck Drugs 2Unity Management Group, MCC Announce Increased Contracts and Major Installations at US and South American Pharmaceutical Companies 2Unity Management Group, MCC Announce Increased Contracts and Major Installations at US and South American Pharmaceutical Companies 3
(Date:5/2/2015)... (PRWEB) May 03, 2015 As one ... of the prestigious Safety and Health Achievement and Recognition ... honored to be chosen by the Illinois Department of ... has achieved and maintained SHARP certification by the Occupational ... 2006, as Essentra has continued to meet or exceed ...
(Date:5/2/2015)... CA (PRWEB) May 02, 2015 ProText Kinetic ... for use in Final Cut Pro X. ProText Kinetic ... use in Final Cut Pro X . Easily ... keyframe with Pixel Film Studios' ProText Kinetic 2. , Using ... Start by staggering two ProText Kinetic presets in the FCPX ...
(Date:5/2/2015)... May 02, 2015 On Tuesday April ... Hospital (ELCH) gathered to celebrate improvements in patient care. ... Health Partners (RVHP), had zero acquired ventilator associated infections, ... associated infections. ELCH was also recently named a Top ... team at ELCH credited the teamwork of staff from ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 With the success ... company is proud to welcome Neida Miranda and Alex Shields ... Dental Consulting has over 41 years of combined experience working ... been in the dental field for 8 years. She ... in Waco, Texas. Customer service, positive attitude and showing the ...
(Date:5/1/2015)... May 01, 2015 Jusuru International has ... the successful repositioning of its flagship nutritional supplement, Liquid ... with a new name, new logo, new packaging, new ... Awards are designed to identify and promote programs that ... , “DSA congratulates Jusuru International for their outstanding ...
Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5
... Expertise to the Beltway , ... New York, NY ... PR firm exclusively serving healthcare, technology and industrial clients, today announced ... media relations approach and public policy expertise to the Beltway. ...
... Investigating Golimumab in the Treatment ... Application, HORSHAM, Pa., June 27 Centocor, ... has been submitted to the U.S.,Food and Drug ... as a monthly subcutaneous treatment for adults with ...
... guest speakers included a World Health Organization expert ... 27 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc. (TSX: BNC), ... conference in Toronto this week,entitled, "E. coli O157 ... veterinarians and representatives from the food industry: Beef,dairy, ...
... Sand Bag , ... St. Louis, MO (PRWEB) June ... residents who were impacted by raging Mississippi waters, last week. In ... were educated on proper sanitation, the importance of hand washing, dehydration, ...
... Insurance, Making Urgent Care Available to More People at a Fraction ... ... June 27, 2008 -- NextCare ( www.nextcare.com ), one of the ... new affordable medical insurance plan, CareForToday. The new medical insurance program ...
... the world will present their latest research on indicators of autism ... identification, and strategies for early intervention. These experts have been discovering ... toddlers to escape the life altering consequences of autism spectrum disorder. ... ...
Cached Medicine News:Health News:Ricochet Public Relations Opens Washington, D.C. Office 2Health News:Ricochet Public Relations Opens Washington, D.C. Office 3Health News:Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2Health News:Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3Health News:Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4Health News:Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5Health News:Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference 2Health News:Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference 3Health News:Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference 4Health News:Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference 5Health News:Sanford-Brown College Students Help in Missouri Flood Relief 2Health News:Urgent Care Provider NextCare Introduces CareForToday Medical Insurance Plan 2Health News:The Second International Conference on Signs of Autism in Infants: Changing Outcomes through Early Identification and Intervention, October 11 and 12, 2008. Save the Date! 2Health News:The Second International Conference on Signs of Autism in Infants: Changing Outcomes through Early Identification and Intervention, October 11 and 12, 2008. Save the Date! 3
Anatomically designed 3 cervical foam collar...
One-piece rigid cervical collar is designed to fit securely around the neck and mandible to provide immobilization and support of the cervical region...
This model utilizes the Malibu Soft Cervical Collar with a Thoracic Extension....
Model C-10 is a four post cervical orthosis which controls flexion, extension, lateral flexion, rotation, and axial motion. Each post may be individually adjusted in height....
Medicine Products: